Insightful Developments and an Exclusive Interview from Roche

Keynote Speaker:David Silverman, Senior Clinical Director, Ophthalmology, Roche

SMi are delighted to have interviewed our speaker David Silverman, Senior Clinical Director, Ophthalmology, Roche regarding his thoughts and experiences within the ophthalmology space.

Snapshot:

Q.What are the biggest developments in the ophthalmic drug industry, and how the future of ocular drug development?

Check out the full interview in the download centre

Roche’s phase III ophthalmology programme is expected to begin later in 2018

Roche announced positive, top-line results from the LADDER study, the first successful phase II study of a long-acting delivery device for the treatment of neovascular (“wet”) age-related macular degeneration (nAMD), a leading cause of blindness globally in people aged 60 and over. LADDER evaluated the efficacy and safety of the investigational Port Delivery System with ranibizumab (PDS) in people with nAMD who had previously responded to treatment with anti-vascular endothelial growth factor (VEGF) therapy. – Source: Roche.com

To hear more about the latest developments from Roche and the future phase III study, register you place today and benefit by hearing David’s Keynote Address on ‘Global reimbursement strategies in ophthalmic clinical development.’

Network with companies such as: MHRA, Santen, Boehringer Ingelheim, Spark Therapeutics, Aerie Pharmaceuticals + more. Download the attendee list onlinewww.ophthalmicdrugs.com/prhq

For those looking to attend, there is currently a £200 early-bird saving, ending September 28^th.

SMi Presents the 2^nd annual:
Ophthalmic Drugs 2018
Date: 26^th – 27^thNovember 2018
Workshops: 28^th November 2018
Location: Copthorne Tara Hotel, London UK
Website:www.ophthalmicdrugs.com/prhq

Sponsors: Experimentica | Nemera

Source: Roche.com

Follow ‘SMi Pharma’ on LinkedIn for latest pharmaceutical industry updates.